FDA Recalls Maximum Zone2 Topical Analgesic Due to Epinephrine Discoloration
HTO Nevada's Maximum Zone2 Topical Analgesic (1oz, Lot #795CP-0003, NDC 80069-012-01) is recalled nationwide in the USA and Canada due to discoloration of the epinephrine active ingredient caused by a manufacturing deviation.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a pharmaceutical product. The documented discoloration of the epinephrine API represents a manufacturing quality defect. No illnesses or injuries have been reported. The product is for professional use only, but qualifies as a risk-of-harm item due to the potent nature of epinephrine.
Plain-English summary
HTO Nevada, Inc., is recalling 1,571 bottles of Maximum Zone2 Topical Analgesic (1oz bottles, NDC 80069-012-01, Lot #795CP-0003, expiration 07/2024) distributed nationwide in the USA and Canada. The product is distributed by DERMAL SOURCE in Portland, Oregon.
The recall is due to discoloration of the epinephrine active pharmaceutical ingredient (API), identified as a current Good Manufacturing Practice (cGMP) deviation in the repackager's raw material. Epinephrine is a critical component of this topical anesthetic formulation used during pain-sensitive procedures in professional settings.
The product is intended for licensed professionals only. No illnesses or injuries have been reported to date. Healthcare facilities and licensed professionals who have received this product should cease use of affected lots and contact DERMAL SOURCE at 1-866-568-3223 or visit www.dermalsource.com for instructions on return and replacement.
The recalled product
- Product
- Maximum Zone2 Topical Analgesic, 1oz bottle, for use during a pain sensitive procedure, distributed by: DERMAL SOURCE, Portland, OR, www.dermalsource.com, 1-866-568-3223, NDC code: 80069-012-01, Drug Facts- For use by licensed professionals only' Active Ingredients- Lidocaine…
- Manufacturer
- HTO Nevada, Inc.
- Affected units
- 1,571
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 795CP-0003
- Exp 07/2024.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by HTO Nevada, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · HTO Nevada, Inc.
See all →- HighNew & Improved Blue Gel Anesthetic Recalled Nationwide for API Discoloration
FDA (Drugs) · 2023-02-22
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-10-14
- HighFDA Recalls Opportunity Pro Nitrile Gloves Due to Manufacturing Defects
FDA (Devices) · 2026-10-07
- HighWright Medical Recalls Charlotte Claw Screws Due to Missing Threads
FDA (Devices) · 2026-10-07
- ModerateCustom Interventional Pain Management Recalls Mastisol Skin Adhesive Trays
FDA (Devices) · 2026-10-07
- HighNOxBOXi Nitric Oxide Delivery System Recalled for Oxygen Sensor Defect
FDA (Devices) · 2026-10-07
Similar recalls
- SevereEpinephrine Active Pharmaceutical Ingredient Recalled for Discoloration
FDA (Drugs) · 2023-02-01
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- SevereEpinephrine API Recalled for Discoloration and Reduced Efficacy
FDA (Drugs) · 2023-02-01
- HighCompounded Lidocaine-Epinephrine Injectable Recalled Nationwide for Subpotent Epinephrine
FDA (Drugs) · 2024-07-17
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- HighEpi-Caine Intraocular Injection Recalled Due to Raw Material Discoloration
FDA (Drugs) · 2023-01-11